The Federal Circuit Bar Association® Patent Litigation Committee Presents:
Latest Developments at the Intersection of FDA and Intellectual Property Law
May 8, 2025
2:00 PM - 3:00 PM ET
Moderator:
Chris Bruno, McDermott Will & Emery LLP
Panelists:
Sue Wang, Sidley Austin LLP
Jake Vallen, McDermott Will & Emery LLP
Summary: Business strategies for both branded and generic pharmaceutical companies can be drastically impacted by changes at the intersection of FDA and intellectual property law. Our panel will discuss recent case developments that carry implications for generic pharmaceutical companies that seek labeling carve-outs to avoid patented indications and the ability of branded and generic companies to benefit from Hatch-Waxman’s Orange Book-listing provisions when seeking to protect or market drug device combination products.
Pricing:
Private Practitioner Cost:
FCBA Member - Complimentary
Non-Member $175
Government/Academic/Retired/Student Cost:
FCBA Member - Complimentary
Non-Member: $50
CLE Information:
FCBA is an approved provider with most states requiring CLE. Individual states have different approval guidelines and timeframes, and the FCBA cannot guarantee a state’s approval of CLE credit for any webcast or other program session.
For information on CLE accreditation, please contact our CLE Manager at cle@fedcirbar.org.